Akeega Patent Expiration

Akeega is a drug owned by Janssen Biotech Inc. It is protected by 11 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 27, 2038. Details of Akeega's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US11673877 Niraparib compositions
Mar, 2038

(13 years from now)

Active
US11091459 Niraparib compositions
Mar, 2038

(13 years from now)

Active
US8071623 Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(6 years from now)

Active
US8436185 Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(4 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11986468 Methods of treating prostate cancer
Jul, 2037

(12 years from now)

Active
US11992486 Methods of treating prostate cancer
Jul, 2037

(12 years from now)

Active
US11986469 Methods of treating prostate cancer
Jul, 2037

(12 years from now)

Active
US11207311 Method of treating prostate cancer
Jul, 2037

(12 years from now)

Active
US8859562 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(6 years from now)

Active
US8143241 DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(2 years from now)

Active
US8071579 DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(2 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Akeega's patents.

Given below is the list of recent legal activities going on the following patents of Akeega.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 14 Sep, 2023 US8143241
Recordation of Patent eGrant 13 Jun, 2023 US11673877
Patent eGrant Notification 13 Jun, 2023 US11673877
Email Notification 13 Jun, 2023 US11673877
Electronic Review 13 Jun, 2023 US11673877
Patent Issue Date Used in PTA Calculation 13 Jun, 2023 US11673877
Recordation of Patent Grant Mailed 13 Jun, 2023 US11673877
Mail Patent eGrant Notification 13 Jun, 2023 US11673877
Email Notification 25 May, 2023 US11673877
Electronic Review 25 May, 2023 US11673877


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Akeega and ongoing litigations to help you estimate the early arrival of Akeega generic.

Akeega's Litigations

Akeega been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Akeega's patents.

Last updated on December 17, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8859562 October, 2011 Decision
(25 Mar, 2014)
Thomas Helleday


FDA has granted some exclusivities to Akeega. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Akeega, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Akeega.

Exclusivity Information

Akeega holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Akeega's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Aug 11, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Akeega's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Akeega's generic, the next section provides detailed information on ongoing and past EP oppositions related to Akeega patents.

Akeega's Oppositions Filed in EPO

Akeega has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2012, by Adams, Harvey Vaughan John. This opposition was filed on patent number EP04743564A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP04798705A May, 2012 STRAWMAN LIMITED Opposition procedure closed
EP04798705A May, 2012 Adams, Harvey Vaughan John Opposition procedure closed
EP04743564A Apr, 2012 STRAWMAN LIMITED Patent maintained as amended
EP04743564A Apr, 2012 Adams, Harvey Vaughan John Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Akeega is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Akeega's family patents as well as insights into ongoing legal events on those patents.

Akeega's Family Patents

Akeega has patent protection in a total of 53 countries. It's US patent count contributes only to 15.2% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Akeega.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Akeega's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 27, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Akeega Generics:

There are no approved generic versions for Akeega as of now.

Alternative Brands for Akeega

Akeega which is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Pharmaand
Rubraca Used for treating cancers associated with deleterious BRCA mutations, such as epithelial ovarian, fallopian tube, primary peritoneal cancer, and metastatic castration-resistant prostate cancer.





About Akeega

Akeega is a drug owned by Janssen Biotech Inc. It is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation. Akeega uses Abiraterone Acetate; Niraparib Tosylate as an active ingredient. Akeega was launched by Janssen Biotech in 2023.

Approval Date:

Akeega was approved by FDA for market use on 11 August, 2023.

Active Ingredient:

Akeega uses Abiraterone Acetate; Niraparib Tosylate as the active ingredient. Check out other Drugs and Companies using Abiraterone Acetate; Niraparib Tosylate ingredient

Treatment:

Akeega is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation.

Dosage:

Akeega is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
500MG;EQ 50MG BASE TABLET Prescription ORAL
500MG;EQ 100MG BASE TABLET Prescription ORAL